

February 07, 2025

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Integrated Filing (Financial) for Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we enclose herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary

Membership No. A23989

Encl: A/a

QUARTERLY INTEGRATED FILING (FINANCIAL)

- A. FINANCIAL RESULTS- **Enclosed below**
- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. - **No Deviation**
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES- **No Default**
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - **Not Applicable for this quarter**
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable for this quarter**

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To


**The Board of Directors of
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Caplin Point Laboratories Limited ('the Company') for the quarter and nine months ended December 31, 2024 ('the Statement').
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai
Date : February 7, 2025



For Brahmayya & Co.,
Chartered Accountants
Firm Regn No. 000511S


N. Sri Krishna
Partner
Membership No. 026575
UDIN: 25026575BMLHBY2274

CAPLIN POINT LABORATORIES LIMITED

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2024

Particulars	Quarter Ended			Nine Months Ended		Year ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(1)	(2)	(3)	(4)	(5)	(6)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
₹ In Crores						
Income:						
I Revenue from operations	185.23	207.93	132.83	578.80	485.71	625.09
II Other income	28.83	43.01	17.90	93.34	69.66	105.84
III Total Income (I+II)	214.06	250.94	150.73	672.14	555.37	730.93
IV Expenses:						
a. Cost of materials consumed	33.29	32.72	43.43	102.39	131.95	172.13
b. Purchase of traded goods	19.24	24.36	13.05	59.78	53.86	76.77
c. Changes in inventories of finished goods, stock in trade and work in progress	8.19	4.70	(14.93)	20.70	(24.09)	(43.68)
d. Employee benefits expense	13.89	12.99	9.52	37.74	28.34	38.11
e. Finance costs	0.04	0.02	0.03	0.08	0.08	0.10
f. Depreciation & Amortisation Expense	6.01	6.49	6.76	18.68	20.15	27.08
g. Other Expenses	33.23	35.00	18.44	101.26	66.26	94.68
Total Expenses	113.89	116.28	76.30	340.63	276.55	365.19
V Profit before exceptional items and Tax (III-IV)	100.17	134.66	74.43	331.51	278.82	365.74
VI Exceptional items	-	-	-	-	-	-
VII Profit Before Tax (V-VI)	100.17	134.66	74.43	331.51	278.82	365.74
VIII Tax Expenses						
(1) Current Tax	25.55	29.15	19.91	79.27	68.90	86.12
(2) Deferred Tax	(0.09)	(0.23)	(0.93)	(0.75)	(3.90)	(4.09)
Total Tax Expenses	25.46	28.92	18.98	78.52	65.00	82.03
IX Net Profit for the period (VII-VIII)	74.71	105.74	55.45	252.99	213.82	283.71
X Other Comprehensive Income/ (Loss) - Net of Tax						
A. Items that will not be re-classified to profit or loss						
i) Remeasurements of Defined Benefit Plan	-	0.16	-	0.16	0.18	(0.21)
B. Items that will be re-classified to profit or loss						
i) Exchange difference in translating the financial statements of foreign operations						
ii) Income tax relating to these items	-	(0.04)	-	(0.04)	(0.04)	0.05
XI Total Comprehensive Income For The Period (IX+X)	74.71	105.86	55.45	253.11	213.96	283.55
XII Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.20	15.20	15.19	15.20	15.19	15.19
XIII Other equity	-	-	-	-	-	1,374.96
XIV Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*						
(a) Basic (in Rupees)	9.83	13.92	7.30	33.30	28.16	37.36
(b) Diluted (in Rupees)	9.77	13.85	7.29	33.12	28.04	37.18
	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)

See Accompanying notes to Financial Results



CAPLIN POINT LABORATORIES LIMITED

Standalone Notes:


- 1) The above Standalone financial Results for the Quarter and Nine Months ended December 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 7, 2025 and also reviewed by the Statutory Auditors.
- 2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments". Hence no separate segment reporting is applicable to the Company.
- 4) Other Income and Profit Before Tax for the Quarter and Nine months ended December 31, 2024 includes Dividend of NIL and ₹20.40 Crores as against NIL and ₹ 19.45 Crores for the Quarter and Nine months ended December 31, 2023, received from Caplin Point Far East Limited, Hong Kong (wholly owned subsidiary).
- 5) During the quarter and Nine months ended December 31, 2024 the Company has allotted NIL equity shares and 69,950 equity shares of ₹ 2/- each under the Employees Stock Option Schemes respectively and the total number of equity shares of the Company stands at 7,60,11,696 as at December 31, 2024 and 7,59,41,746 as at December 31, 2023. The Company had allotted 1000 shares and 39,000 shares during the quarter ended and Nine months ended December 31, 2023 respectively.
- 6) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.

For and on behalf of the Board

Place: Chennai
Date: February 7, 2025



Dr. Sridhar Ganesan
Managing Director



Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

**The Board of Directors of
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Caplin Point Laboratories Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its share of net profit / (loss) after tax and total comprehensive income / loss of associate for the quarter and nine months ended December 31, 2024 being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The statement includes results of the following entities:

Subsidiary Companies

Name of the Entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud Pharma LLP, India	Subsidiary (LLP)
Caplin One Labs Limited, India (Formerly known as Caplin Onco Limited)	Wholly owned subsidiary
Caplin Point Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point (S) Pte. Ltd, Singapore	Wholly owned subsidiary

Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)

Name of the Entity	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Step Down Subsidiary
Nuevos Eticos Neo Ethicals S.A, Guatemala	Step Down Subsidiary
Neoethicals CIA.LTDA, Ecuador	Step Down Subsidiary
Drogueria Saimed de Honduras S.A., Honduras	Step Down Subsidiary
Neo Ethicals S.A, Nicaragua	Step Down Subsidiary
Caplin Point Laboratories Colombia SAS, Colombia	Step Down Subsidiary

Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)

Name of the Entity	Relationship
Caplin Steriles USA Inc., USA	Step Down Subsidiary

Associate Company of Caplin Steriles Limited

Name of the Entity	Relationship
Sunsole Solar Private Limited	Associate



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statement / financial information / financial results of four subsidiaries and five step-down subsidiaries included in the Statement, whose interim financial statement / financial information / financial results reflect total revenues of Rs. 308.53 Crores and Rs. 831.69 Crores, total net profit of Rs. 68.73 Crores and Rs. 150.67 Crores, other comprehensive income of Rs. 23.06 Crores and Rs. 29.02 Crores for the quarter and nine months ended on December 31, 2024 respectively, as considered in the Unaudited Consolidated Financial Results. These interim financial statement / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in Paragraph 3 above. Our conclusion on the statement is not modified in respect of this matter.
7. The Statement includes the interim financial statement / financial information / financial results of one subsidiary and two step-down subsidiary which have not been reviewed, whose interim financial statement / financial information / financial results reflect total revenues of Rs. 1.73 Crores and Rs. 1.88 Crores, net loss after tax of Rs. 3.36 Crores and Rs. 7.85 Crores and other comprehensive loss of Rs. 0.25 Crores and Rs. 0.32 Crores for the quarter and nine months ended December 31, 2024, as considered in the Unaudited Consolidated Financial Result. The Statement also includes the Group's share of net loss of Rs. 0.01 Crores and Rs. 0.09 Crores, other comprehensive income of Rs. Nil and Rs. Nil for the quarter and nine months ended December 31, 2024 as considered in the unaudited consolidated financial result, in respect of one associate, based on their interim financial statements / financial information / financial results, which have not been reviewed. According to the information and explanations given to us by the management, these financial statements / financial information / financial results of aforesaid subsidiaries, step down subsidiaries and associate are not material to the Group. Our review conclusion is not modified in respect of this matter.

Place : Chennai

Date : February 7, 2025




For Brahmayya & Co.,
Chartered Accountants
Firm Regn No. 000511S


N. Sri Krishna
Partner

Membership No. 026575
UDIN: 25026575BMLHQBZ3929

CAPLIN POINT LABORATORIES LIMITED							
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2024							
Particulars	Quarter Ended			Nine Months Ended		Year ended	
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024	
	(1)	(2)	(3)	(4)	(5)	(6)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
₹ in Crores							
Income:							
I Revenue from operations	492.96	483.10	435.50	1,435.02	1,240.88	1,694.10	
II Other income	31.36	20.77	17.18	70.69	49.65	66.94	
III Total Income (I+II)	524.32	503.87	452.68	1,505.71	1,290.53	1,761.04	
IV Expenses:							
a. Cost of materials consumed	59.80	69.23	50.95	187.61	181.94	267.10	
b. Purchase of traded goods	139.43	126.07	179.77	436.93	437.14	499.78	
c. Changes in inventories of finished goods, stock in trade and work in progress	(3.88)	(6.48)	(40.61)	(54.90)	(86.27)	(42.70)	
d. Employee benefits expense	46.77	44.29	36.67	131.21	106.82	143.59	
e. Finance costs	0.18	0.21	0.17	0.44	0.63	0.78	
f. Depreciation & Amortisation Expense	16.20	16.76	13.90	48.92	37.04	53.44	
g. Other Expenses	88.55	85.23	66.44	255.30	195.04	274.89	
Total Expenses	347.05	335.31	307.29	1,005.51	872.34	1,196.88	
V Profit before share of profit in Associate, Exceptional Items and tax (III-IV)	177.27	168.56	145.39	500.20	418.19	564.16	
VI Share of Profit in Associate	(0.01)	(0.10)	0.02	(0.09)	0.21	0.27	
VII Exceptional items	-	-	-	-	-	-	
VIII Profit Before Tax (V+VI+VII)	177.26	168.46	145.41	500.11	418.40	564.43	
IX Tax Expenses							
(1) Current Tax	34.22	32.46	26.01	96.06	80.98	101.55	
(2) Deferred Tax	2.97	5.19	(0.42)	8.24	(2.77)	1.46	
Total Tax Expenses	37.19	37.65	25.59	104.30	78.21	103.01	
X Net Profit for the period (VIII - IX)	140.07	130.81	119.82	395.81	340.19	461.42	
XI Other Comprehensive Income - Net of Tax							
A. Items that will not be re-classified to profit or loss							
i) Remeasurements of Defined Benefit Plan	0.04	0.38	0.04	0.42	0.51	(0.04)	
ii) Income tax relating to these items	(0.02)	(0.09)	(0.01)	(0.11)	(0.13)	0.01	
B. Items that will be re-classified to profit or loss							
i) Exchange difference in translating the financial statements of foreign operations	22.79	1.04	0.83	28.51	7.82	11.48	
XII Total Comprehensive Income For The Period (X + XI)	162.88	132.14	120.68	424.63	348.39	472.87	
XIII Profit attributable to:							
Owners of the Company	138.96	130.80	117.20	393.74	335.50	457.09	
Non- controlling interests	1.11	0.01	2.62	2.07	4.69	4.33	
	140.07	130.81	119.82	395.81	340.19	461.42	
XIV Total Comprehensive Income For The Period attributable to							
Owners of the Company	161.77	132.13	118.06	422.56	343.70	468.54	
Non- controlling interests	1.11	0.01	2.62	2.07	4.69	4.33	
	162.88	132.14	120.68	424.63	348.39	472.87	
XV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.20	15.20	15.19	15.20	15.19	15.19	
XVI Other equity excluding Non-controlling interest						2,300.52	
XVII Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*							
(a) Basic (in Rupees)	18.28	17.22	15.44	51.82	44.19	60.19	
(b) Diluted (in Rupees)	18.19	17.12	15.39	51.55	44.00	59.90	
	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)	

See Accompanying notes to Financial Results



CAPLIN POINT LABORATORIES LIMITED

Consolidated Notes:

- 1) The above Consolidated Financial Results for the Quarter and Nine months ended December 31, 2024 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on February 7, 2025 and also reviewed by the Statutory Auditors.
- 2) The unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments". Hence no separate segment reporting is applicable to the Company.
- 4) During the quarter and Nine months ended December 31, 2024 the Company has allotted NIL equity shares and 69,950 equity shares of ₹ 2/- each under the Employees Stock Option Schemes respectively and the total number of equity shares of the Company stands at 7,60,11,696 as at December 31, 2024 and 7,59,41,746 as at December 31, 2023. The Company had allotted 1000 shares and 39,000 shares during the quarter ended and Nine months ended December 31, 2023 respectively.
- 5) Caplin Steriles Limited, a subsidiary of the Company, had leased an external warehouse from a third-party agency in Chennai for the temporary storage of newly imported plant and machinery valued at ₹30.46 crores. These assets were duly insured.

During the Michaung Cyclone that impacted Chennai in December 2023, the machinery stored awaiting installation was severely damaged by floods. Joint inspections conducted by the Original Equipment Manufacturers (OEMs) and Insurance Surveyors who confirmed the damage, with the OEMs declared the machinery as a total loss. However, the Insurance Surveyors claimed/stated discrepancies in the insured address among other aspects and, based on their findings, the insurers denied the claim, issuing a "No Claim" notice.

In response, the Company has made representations to various forums and is in the process of initiating legal proceedings to secure a complete settlement of its legitimate claims due to flood damage. Thus, notwithstanding the NO CLAIM NOTICE, given the strong and favourable legal opinion supporting the stand of the company, the Company firmly believes that the litigation outcome will be positive and accordingly continues to treat the insurance claim as recoverable at its value.
- 6) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.

For and on behalf of the Board



Sridhar

Dr. Sridhar Ganesan
Managing Director

Place: Chennai
Date: February 7, 2025

